Regeneron Pharmaceuticals, Inc., founded in 1988 by Leonard Schleifer and George Yancopoulos, is a leading American biotechnology company based in Westchester County, New York. Renowned for innovative drug development, Regeneron employs proprietary technologies like VelocImmune, which produces optimized antibodies using genetically humanized mice. The company’s diverse portfolio includes FDA-approved treatments for eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, and rare disorders. In collaboration with Sanofi, Regeneron developed Dupixent, a significant medication for various chronic diseases driven by type 2 inflammation.